Awakn Life Sciences Corp. (AWKNF) Stock Price, News, Quote & History - Yahoo Finance
Canada markets closed

Awakn Life Sciences Corp. (AWKNF)

OTC Markets OTCQB - OTC Markets OTCQB Delayed Price. Currency in USD
Add to watchlist
0.1042-0.0058 (-5.27%)
At close: 09:30AM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.1100
Open0.1042
Bid0.0910 x 0
Ask0.1042 x 0
Day's Range0.1042 - 0.1042
52 Week Range0.0422 - 0.2600
Volume1,899
Avg. Volume9,191
Market Cap4.118M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.1000
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile

    Awakn Life Sciences Announces Closing of Tranche of Private Placement

    Toronto, Ontario--(Newsfile Corp. - June 4, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company") a clinical-stage biotechnology company developing medication-assisted treatments for addiction with a near-term focus on Alcohol Use Disorder, is pleased to announce that, further to its press releases dated April 3, 2024, and April 17, 2024, it has closed a second tranche (the "Second Tranche") of its previously announced non-brokered private placement (

  • Market Exclusive

    Weekly Roundup on the Cannabis Sector & Psychedelic Sector

    Key Takeaways; Cannabis Sector Canopy Growth secured $50M financing, and restructured debt with an institutional investor. High Tide appointed a new CFO, as the company eyes long-term growth. SNDL intends to move forward with Parallel and Skymint acquisitions, despites the deals facing litigation. Schwazze settled wage theft claims amidst another legal challenges. Key Takeaways; Psychedelic […]

  • Newsfile

    Awakn Life Sciences Discusses Filing of Financial Statements

    Toronto, Ontario--(Newsfile Corp. - May 2, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a clinical-stage biotechnology company developing medication-assisted treatments for addiction with a near-term focus on Alcohol Use Disorder (AUD), announces that, it intends to file its audited annual financial statements and MD&A for the financial year ended January 31, 2024 (the "Financial Statements") by May 30, 2024, in line with the standard timeli